[ad_1]
The “Artificial Intelligence in Drug Discovery Market Share, Size, Trends, Industry Analysis Report, By Application; By Therapeutic Area; By Offering; By Technology; By Region; Segment Forecast, 2022 – 2029” report has been added to ResearchAndMarkets.com’s offering.
The global artificial intelligence in drug discovery market size is expected to reach USD 5,558.0 million by 2029
Artificial Intelligence (AI) uses complex algorithms and machine learning to acquire significant information from huge datasets. For instance, AI uses RNA sequencing data to recognize genes whose expression correlates with a given cellular condition.
It employs the most recent advancements in biology to create cutting-edge medicine discovery algorithms. The increase in computer processing power, the development of advanced algorithms, and the availability of large datasets are the main drivers that led to the developments in machine learning.
Based on application, the global artificial intelligence (AI) in the drug discovery market is clustered into drug optimization & repurposing, preclinical testing, and others. The optimization & repurposing segment accounted for the largest revenue share in the industry as it is economical and demands only Electronic Medical Records (EMR) for medicine repurposing.
Based on therapeutic areas, the global market is classified into oncology, neurodegenerative diseases, cardiovascular disease, metabolic diseases, infectious diseases, and others. The oncology segment accounted for the largest revenue share in 2020 as it deals with the diagnosis and prevention of cancer.
There are some pharmaceutical companies that are focusing on integrating artificial intelligence with medicine discovery and development. For instance, Pfizer associated with IBM Watson Health, an AI platform, to augment their search for immuno-oncology treatments. Sanofi partnered with Exscientia to discover metabolic-disease therapies.
The companies in the…
[ad_2]
